Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 9/20 | 0.43 |
| ▸ | FDPS | P14324 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
| ▸ | LAP3 | P28838 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.35 |
| ▸ | CES1 | P23141 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL73702 | 0.75 | FDPS (0.44) | PTPN1FDPSPTPRCLAP3SMN1; SMN2 | |
| SCHEMBL28369074 | 0.75 | SMN1; SMN2 (0.50) | PTPN1FDPSPTPRCSMN1; SMN2HIF1A | |
| SCHEMBL7316714 | 0.75 | SMN1; SMN2 (0.50) | PTPN1FDPSPTPRCSMN1; SMN2HIF1A | |
| SCHEMBL29112713 | 0.72 | SMN1; SMN2 (0.50) | PTPN1FDPSSMN1; SMN2HIF1APPARG | |
| SCHEMBL30887346 | 0.72 | SMN1; SMN2 (0.50) | PTPN1FDPSSMN1; SMN2HIF1APPARG | |
| SCHEMBL3736878 | 0.72 | SMN1; SMN2 (0.50) | PTPN1FDPSSMN1; SMN2HIF1APPARG | |
| SCHEMBL29510761 | 0.71 | SMN1; SMN2 (0.46) | SMN1; SMN2HIF1ALMNACES1 | |
| SCHEMBL33528430 | 0.70 | L3MBTL1 (0.41) | SMN1; SMN2HIF1APPARGPPARA | |
| SCHEMBL26127150 | 0.70 | SMN1; SMN2 (0.44) | PTPN1FDPSSMN1; SMN2HIF1APPARG | |
| SCHEMBL8414267 | 0.69 | PTPN1 (0.39) | PTPN1FDPSPTPRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159442-A1 | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors and methods of using the same | JANSSEN PHARMACEUTICA NV (BE) | 2005-07-21 | — | — | US | disclosed |
| WO-2005044277-A1 | PROTEIN TYROSINE PHOSPHATASE 1B (PTP-1B) INHIBITORS AND METHODS OF USING THE SAME | JANSSEN PHARMACEUTICA NV (BE) | 2005-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050159442-A1 | Protein tyrosine phosphatase 1B (PTP-1B) inhibitors and methods of using the same | PTPRM, PTPRS, PTPRR | PTPN1 8/4885FDPS 2489/4885PTPRC 14/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.